AbbVie’s Humira tops ICER’s list of unwarranted price hikes again
AbbVie, Biogen, Humira, ICER, medicines spending, Novartis, pricing, Promacta, Tysabri, US
0 Comment
Promacta
Sobi gets EU nod for Doptelet in rare blood disorder ITP
Doptelet, ema, Grifols, immune thrombocytopenia, Novartis, Promacta, rare disease, regulatory approval, Rigel Pharmaceuticals, SOBI
0 Comment
Novartis’ severe aplastic anaemia drug fast-tracked by FDA
blood disorder, cancer, Novartis, Priority Review, Promacta, SAA, severe aplastic anaemia, solid tumour
0 Comment
The FDA has accepted Novartis’ supplemental New Drug Application (sNDA) and granted Priority Review designation to Promacta (eltrombopag) in combination with standard immunosuppressive therapy (IST) for first-line treatment of severe aplastic anaemia (SAA), a rare and serious blood condition.
Novartis adds Promacta to breakthrough status roll-call
Breakthrough Therapy Designation, GlaxoSmithKline, Haematology, Novartis, Promacta, regulation
0 Comment
Drug could get new indication based on NIH research